Literature DB >> 18380911

Gene therapy for osteosarcoma: steps towards clinical studies.

Crispin R Dass1, Peter F M Choong.   

Abstract

Gene therapy, an applied form of biotechnology, relies on the delivery of foreign DNA into cells. More than 50% of all reported clinical trials for gene therapy are for cancer, though only a scant number for osteosarcoma. Osteosarcoma is a neoplasm afflicting young adults, who in their prime years of life suffer debilitation if not death. The disease is not entirely curable, even with surgery combined with aggressive chemotherapy. Thus, other forms of therapies are being evaluated, including gene therapy. There exist two major forms of gene transfer: viral and non-viral. This review only covers proof-of-principle work carried out in cancer beyond the cell culture stage, in animals. Drawing from the experiences of gene therapy against other cancers, studies for which have already reached the clinical phase, the review discusses potential pitfalls and solutions to enhance gene therapy for osteosarcoma.

Entities:  

Mesh:

Year:  2008        PMID: 18380911     DOI: 10.1211/jpp.60.4.0001

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  7 in total

1.  Lentivirus-mediated RNAi knockdown of prostate-specific membrane antigen suppresses growth, reduces migration ability and the invasiveness of prostate cancer cells.

Authors:  Zhenghui Guo; Hai Huang; Lexiang Zeng; Tao Du; Kewei Xu; Tianxin Lin; Chun Jiang; Wen Dong; Yi Cao; Jieqing Chen; WeiDe Zhong; Jian Huang
Journal:  Med Oncol       Date:  2011-09       Impact factor: 3.064

2.  Identification of MAP3K15 as a potential prognostic biomarker and correlation with immune infiltrates in osteosarcoma.

Authors:  Zhuning Chen; Haoran Kong; Zhaopeng Cai; Keng Chen; Boyang Wu; Haonan Li; Peng Wang; Yanfeng Wu; Huiyong Shen
Journal:  Ann Transl Med       Date:  2021-07

3.  Lentivirus-mediated RNAi knockdown of insulin-like growth factor-1 receptor inhibits growth, reduces invasion, and enhances radiosensitivity in human osteosarcoma cells.

Authors:  Yin-He Wang; Zhao-Xia Wang; Yong Qiu; Jin Xiong; Yi-Xin Chen; Deng-Shun Miao; Wei De
Journal:  Mol Cell Biochem       Date:  2009-02-20       Impact factor: 3.396

4.  Expression of Beclin1 in osteosarcoma and the effects of down-regulation of autophagy on the chemotherapeutic sensitivity.

Authors:  Zhicai Zhang; Zengwu Shao; Liming Xiong; Biao Che; Chao Deng; Weiwei Xu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-12-29

Review 5.  Osteosarcoma: a review of current and future therapeutic approaches.

Authors:  Xin Zhao; Qirui Wu; Xiuqing Gong; Jinfeng Liu; Yujie Ma
Journal:  Biomed Eng Online       Date:  2021-03-02       Impact factor: 2.819

6.  Novel approaches for treating musculoskeletal diseases: molecular orthopedics and systems medicine.

Authors:  Kaveh Mashayekhi; Margaret O'Brien; Florin Zugun-Eloae; Luminita Labusca
Journal:  Open Orthop J       Date:  2013-05-03

7.  Long non-coding RNA TUSC7 suppresses osteosarcoma by targeting miR-211.

Authors:  Menglin Cong; Rui Jing
Journal:  Biosci Rep       Date:  2019-11-29       Impact factor: 3.840

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.